Tags: IBD, ulcerative colitis, TL1A, phase 3, immunology, pipeline competition

Merck posts first phase 3 TL1A win in ulcerative colitis and puts the IBD field on notice

By FieldPulse Editorial · June 22, 2026

Merck says tulisokibart became the first anti-TL1A antibody to show phase 3 clinical-remission data in ulcerative colitis, raising the competitive temperature in IBD.

Merck has delivered the kind of immunology readout competitors were waiting for.

The company said tulisokibart met the primary and key secondary endpoints in the phase 3 ATLAS-UC induction-only study in adults with moderately to severely active ulcerative colitis, making it the first anti-TL1A monoclonal antibody to show clinical remission at 12 weeks in a phase 3 trial.

That matters well beyond a pipeline tracker.

TL1A has been one of the most watched targets in inflammatory bowel disease because companies are looking for new ways to compete in a market still dominated by established biologics and advanced immunology brands.

Merck said tulisokibart is designed to target TL1A, a pathway linked to inflammation and fibrosis, and framed the result as an important step for patients who still do not achieve remission with current options.

For Merck, this is a meaningful commercial signal.

The company bought Prometheus Biosciences to get this asset and has spent the last few years building more visible credibility in immunology.

A positive phase 3 induction study does not equal launch readiness, but it does move the program from theoretical promise to a far more concrete competitive threat.

The value for field teams is in how the readout changes category conversations.

Late-stage success gives Merck a stronger reason to talk internally about where it wants to build presence in gastroenterology and immunology, and it gives competing teams a new pipeline entrant they cannot dismiss as an early-science story.

In other words, this is no longer just target enthusiasm.

It is now a late-stage mechanism with real data behind it.

That is the main field-team angle.

If you cover IBD for Merck, this is the sort of pipeline milestone that helps explain where the company wants to compete next.

If you cover the category for AbbVie, Johnson & Johnson, or Takeda, it is a reminder that the next wave of competition may focus not only on label breadth and sequencing, but also on mechanism-ba.